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MaBACKGROUND Atrial ﬁbrillation (AF) is common in patients with the HeartMate II (HMII) left ventricular assist device
(LVAD), but the impact of AF on clinical outcomes is uncertain.
OBJECTIVES This study sought to determine the effect of AF on outcomes in patients with the HMII LVAD.
METHODS Records of 106 patients who underwent HMII implantation at a single center were reviewed. The associations of
paroxysmal atrial ﬁbrillation (PAF) and persistent atrial ﬁbrillation (PeAF) with survival, heart failure (HF) hospitalization,
bleeding,and thromboembolismwereexaminedusingKaplan-Meier survival analysis andCoxproportionalhazards regression.
RESULTS Mean age was 56.6  11.4 years, 87.7% of the implants were intended as a bridge to transplantation, and
median length of support was 217 days (range: 1 to 952 days). AF was present in 55 patients (51.9%); 36 patients (34.0%)
had PAF and 19 (17.9%) had PeAF. Twenty-one patients (19.8%) died, and 18 (17.0%) were hospitalized for HF. There
were 0.75 major bleeding events and 0.28 thromboembolic events per patient year of follow-up. PAF was not associated
with increased mortality, HF hospitalization, bleeding, or thromboembolism. PeAF, however, was an independent pre-
dictor of the composite endpoint of death or HF hospitalization (hazard ratio: 3.54; 95% conﬁdence interval: 1.52 to 8.25;
p < 0.01). Although there was no increase in bleeding or thromboembolism, patients with AF had thromboembolic
events at higher international normalized ratios (INRs).
CONCLUSIONS Although PAF is not associated with worse outcomes in patients with the HMII LVAD, PeAF may be
associated with increased mortality and HF hospitalization. Patients with AF also may have thromboembolic events at
higher INR levels. (J Am Coll Cardiol 2014;64:1883–90) © 2014 by the American College of Cardiology Foundation.A trial ﬁbrillation (AF) is common in patientswith end-stage heart failure (HF) and is pre-sent in up to 50% of patients (1). AF pre-
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ABBR EV I A T I ON S
AND ACRONYMS
AF = atrial ﬁbrillation
CF-LVAD = continuous ﬂow
left ventricular assist device
CPET = cardiopulmonary
exercise test
CVA = cerebrovascular
accident
HF = heart failure
HM II = HeartMate II
ICH = intracranial hemorrhage
PAF = paroxysmal
atrial ﬁbrillation
PeAF = persistent
atrial ﬁbrillation
RV = right ventricular/ventricle
TIA = transient ischemic attack
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1884targeting an international normalized ratio
(INR) of 1.5 to 2.0 for patients without AF
and 2.0 to 2.5 for those with AF (5). Accord-
ingly, AF may affect outcomes through an
increased risk of bleeding due to the higher
level of anticoagulation therapy. Therefore,
we sought to determine the effect of AF
on mortality, HF hospitalization, bleeding,
and thromboembolism in patients with CF-
LVADs.
METHODS
We reviewed the records of consecutive adult
patients receiving the HeartMate II (HMII;
Thoratec Corp., Pleasanton, California) LVAD
at theMount Sinai Medical Center in NewYork
between June 2008 and April 2012. Patients
were followed until 1 of the following end-points was reached: death, transplantation, HMII
explantation, end of follow-up period, or loss to
follow-up. The Institutional Review Board of the Icahn
School ofMedicine atMount Sinai approved this study.SEE PAGE 1891ATRIAL FIBRILLATION AND ANTICOAGULATION.
Retrospective chart reviews of electrocardiograms,
device interrogations, and progress notes were per-
formed to evaluate for AF occurrence. AF was deﬁned
as the presence of preoperative AF or the develop-
ment of AF post-LVAD past the perioperative period
(>30 days). AF was further subdivided into parox-
ysmal atrial ﬁbrillation (PAF) and persistent atrial
ﬁbrillation (PeAF), using standard deﬁnitions (1).
Because outcomes may differ between these groups,
patients were analyzed in 3 groups: 1) those who did
not have AF; 2) those who had PAF; and 3) those who
had PeAF. The management of AF post-LVAD was
left to the discretion of the HF specialist. In terms of
anticoagulation, all patients received aspirin, 81 mg
daily, and warfarin. For patients without AF, the INR
goal was 1.5 to 2.0. For all patients with AF, the INR
goal was 2.0 to 2.5. If a patient had multiple bleeding
events, the INR goal was decreased to 1.5 to 2.0 in
patients with AF.
ATRIAL FIBRILLATION AND OUTCOMES. The focus
of the study was the impact of PAF and PeAF on
the following 3 outcomes: survival or HF hospitali-
zation, thromboembolism, and bleeding. All deaths
were conﬁrmed through examination of the medical
record, and the cause of death was noted. HF hos-
pitalization was deﬁned as hospitalization for signs
of right HF (e.g., jugular venous distension, lower
extremity edema) requiring escalation of diuretictherapy and/or initiation of inotrope therapy.
Thromboembolism was deﬁned as cerebrovascular
accident (CVA), transient ischemic attack (TIA), arte-
rial thromboembolism, or conﬁrmed LVAD pump
thrombosis. Major bleeding was deﬁned using the
Interagency Registry of Mechanically Assisted Circu-
latory Support (INTERMACS) deﬁnition (6). However,
intracranial hemorrhage (ICH) also was included in
major bleeding. The INR at the time of each bleeding
and thromboembolic event was recorded. For
thromboembolic events, a 4-week mean INR prior to
the event also was calculated.
ATRIAL FIBRILLATION AND FUNCTIONAL STATUS.
Patients deemed suitable by the HF specialist un-
derwent a cardiopulmonary exercise test (CPET) $3
months after LVAD implantation. The CPET was per-
formed on a treadmill, using a modiﬁed Naughton
protocol. Oxygen consumption (VO2) was continu-
ously measured, and the test was symptom limited.
Peak Vo2 levels of patients without AF were compared
with those of patients with PAF and PeAF.
STATISTICAL ANALYSIS. Categorical variables were
evaluated using the chi-square or Fisher exact test.
Continuous variables were analyzed with the t-test or
Mann-Whitney U test. Normally distributed contin-
uous variables were expressed as mean  SD; non-
normal variables were expressed as medians with
interquartile ranges (IQR). For survival analysis,
Kaplan-Meier time-to-event curves stratiﬁed by AF
status were generated for death or HF hospitalization,
thromboembolism, and bleeding. Statistical signiﬁ-
cance between the curves was analyzed using the
log-rank test. The effect of AF and other variables on
each outcome was analyzed using Cox proportional
hazards regression. Because of the relatively small
number of events for each outcome, multivariable
regression was performed only for the composite
outcome. Variables with a p value of <0.10 in uni-
variable analysis were included in the multivariable
model. All p values were 2-tailed, and the level of
signiﬁcance for all p values was <0.05. No corrections
were used for multiple comparisons. Conﬁdence in-
tervals (CIs) were computed at the 95% conﬁdence
level. All statistics were computed using Stata
version 12.0 (StataCorp, College Station, Texas).
RESULTS
DEMOGRAPHICS. During the study period, 106 pa-
tients received the HMII device, and 9 patients also
received a temporary RV assist device at the time of
LVAD implantation. Only 1 patient underwent an
(unsuccessful) Cryo-Maze (Medtronic, Minneapolis,
Minnesota) procedure during LVAD implantation,
0 100 200 300 400
Support Time
0.00
0.25
0.50
0.75
1.00
Ev
en
t-
Fr
ee
 S
ur
vi
va
l
Number at risk
No AF
Paroxysmal AF
Persistent AF
51
36
19
37
27
9
27
20
5
14
12
2
Log-rank: p < 0.001
7
8
2
No AF Persistent AFParoxysmal AF
FIGURE 1 Kaplan-Meier Survival Curves for the
Composite Endpoint of All-Cause Mortality or
Heart Failure Hospitalization
Kaplan-Meier survival curves are shown for the composite
endpoint of all-cause mortality or heart failure hospitalization
stratiﬁed by atrial ﬁbrillation status. AF ¼ atrial ﬁbrillation.
TABLE 1 Baseline Characteristics Stratiﬁed by AF Status (n ¼ 106)
Variable
Number
of Patients
Without AF
(n ¼ 51, 48.1%)
Number of
Patients With
Paroxysmal AF
(n ¼ 36, 34.0%)
Number of
Patients With
Persistent AF
(n ¼ 19, 17.9%)
Age, yrs 53.0  12.3 59.4  9.8* 61.0  8.3*
Male 43 (84.3) 29 (80.6) 15 (78.9)
Caucasian 21 (41.2) 24 (66.7)* 13 (68.4)*
Ischemic cardiomyopathy 23 (45.1) 16 (44.4) 6 (31.6)
Onset of heart failure >1 year 36 (70.6) 30 (83.3) 18 (94.7)*
Implantable cardioverter-deﬁbrillator 34 (66.7) 31 (86.1)* 18 (94.7)*
Diabetes 17 (33.3) 20 (55.6)* 9 (47.4)
Chronic kidney disease
(stage III and above)
16 (31.4) 17 (47.2) 12 (63.2)*
CHADS2 1.8  0.8 2.5  1.2* 2.3  1.0
History of stroke 0 (0.0) 6 (16.7)* 1 (5.3)
Medications
Beta-blockers 23 (45.1) 26 (72.2)* 17 (89.5)*
Amiodarone 10 (19.6) 15 (41.7)* 12 (63.2)*
Left ventricular ejection fraction, % 18.5  7.4 18.9  6.6 17.0  8.0
Severe right ventricular
dysfunction (2-dimensional
visual estimation)
27 (52.9) 15 (41.7) 12 (63.2)
Pre-LVAD pulmonary vascular
resistance, Wood units
3.35  2.55 3.16  1.77 3.11  2.00
LVAD as bridge to transplantation 48 (94.1) 30 (83.3) 15 (79.9)
INTERMACS level
1 19 (37.3) 6 (16.7)* 5 (26.3)
2 14 (27.5) 10 (27.8) 4 (21.1)
3 14 (27.5) 19 (52.8)* 8 (42.1)
4 4 (7.8) 1 (2.8) 2 (10.5)
Right ventricular assist device 6 (11.8) 2 (5.6) 1 (5.3)
Values are mean  SD or n (%). *p < 0.05 compared to the group without AF.
AF ¼ atrial ﬁbrillation; CHADS2 ¼ Congestive heart failure, hypertension, age $75, diabetes mellitus, prior
stroke or transient ischemic attack; INTERMACS ¼ Interagency Registry for Mechanically Assisted Circulatory
Support; LVAD ¼ left ventricular assist device.
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1885and 2 patients underwent left atrial appendage liga-
tion. Overall, the majority of patients were male
(82.1%), had a non-ischemic cardiomyopathy (57.5%),
and received the HMII as a bridge to transplantation
(87.7%). Mean age was 56.6  11.4 years, and mean left
ventricular ejection fraction (LVEF) was 18.4  7.2%.
The median support time was 217 days (range: 1 to 952
days), and there were 73.7 patient years of total sup-
port time. All patients were classiﬁed as New York
Heart Association functional class III to IV and had
INTERMACS proﬁles 1 to 4 at the time of HMII im-
plantation. Twenty-one patients (19.8%) died, 60 sur-
vived to transplantation (56.6%), 3 (2.8%) had theHMII
explanted because of myocardial recovery, 19 (17.9%)
reached the end of follow-up, and 3 patients (2.8%)
were followed at other centers after implantation.
AF was present in 55 patients (51.9%). Fifty pa-
tients had pre-LVAD AF, and 5 patients developed AF
past the postoperative period (>30 days after im-
plantation). Thirty-six patients (34.0%) had PAF, and
19 (17.9%) had PeAF. The baseline characteristics of
patients with PAF, PeAF, and no AF are shown
in Table 1. Compared to patients without AF, those
with PAF and PeAF were more likely to be older,
Caucasian, have a diagnosis of HF for >1 year, have
an implantable cardioverter-deﬁbrillator, and be re-
ceiving a beta-blocker and/or amiodarone prior to
LVAD implantation. Patients with PAF were more
likely to have had CVA, and those with PeAF were
more likely to have chronic kidney disease. There
were no statistically signiﬁcant differences between
the PAF and PeAF groups.
ATRIAL FIBRILLATION, SURVIVAL, AND HOSPITAL-
IZATION FOR HEART FAILURE. Thirty-seven pa-
tients reached the composite endpoint of death or HF
hospitalization: 13 (25.5%) in the no AF group, 11
(30.6%) in the PAF group, and 13 (68.4%) in the PeAF
group. Patients with PeAF were at increased risk for
death or HF hospitalization compared to the other
groups (log-rank: p < 0.001) (Figure 1). In multivari-
able regression analysis with PAF, PeAF, destination
therapy LVAD, and LVAD implant creatinine level as
covariates, PAF was not associated with an increased
risk of reaching the composite endpoint (hazard ratio
[HR]: 0.91; 95% CI: 0.38 to 2.20; p ¼ 0.83), but PeAF
remained an independent predictor of the composite
endpoint (HR: 3.54; 95% CI: 1.52 to 8.25; p ¼ 0.003).
Implant creatinine level was also a signiﬁcant pre-
dictor of the composite endpoint (HR: 1.48; 95% CI:
1.21 to 1.81; p < 0.01).
The associations between PAF and PeAF and the
individual components of the composite endpoint are
shown in Table 2. Twenty-one patients died during
the study period, with 9 (17.7%) in the no AF group, 5
TABLE 2 Regression Analysis of PAF and PeAF With Each Clinical Outcome
Outcome
PAF PeAF
HR 95% CI p Value HR 95% CI p Value
Death or HF hospitalization* 0.91 0.38–2.20 0.83 3.54 1.52–8.25 <0.01
Death 0.77 0.25–2.40 0.65 2.65 0.96–7.35 0.06
HF hospitalization 2.18 0.64–7.47 0.21 7.37 2.12–25.64 <0.01
Bleeding 1.38 0.64–2.99 0.41 1.09 0.39–3.05 0.88
Thromboembolism 0.84 0.30–2.36 0.75 0.30 0.04–2.36 0.25
*Multivariable regression analysis.
CI ¼ conﬁdence interval; HF ¼ heart failure; HR ¼ hazard ratio; PAF ¼ paroxysmal atrial ﬁbrillation;
PeAF ¼ persistent atrial ﬁbrillation.
TABLE 3 Causes of D
Cause of Death
Right heart failure
Sepsis
Respiratory failure
Intracranial hemorrhag
Thromboembolism
Unknown
Values are n (%).
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1886(13.9%) in the PAF group, and 7 (36.8%) in the PeAF
group. The causes of death in each group are shown
in Table 3. In regression analysis, PAF was not
associated with an increased risk of death (HR: 0.77;
95% CI: 0.25 to 2.40; p ¼ 0.65). There was a strong
trend toward increased mortality in the PeAF group,
but this did not reach statistical signiﬁcance (HR:
2.65; 95% CI: 0.96 to 7.35; p ¼ 0.06). Having the
LVAD implanted as destination therapy was the
only signiﬁcant predictor of death in regression
analysis (HR: 3.69; 95% CI: 1.40 to 9.72; p < 0.01).
Eighteen patients (17.0%) were hospitalized for HF,
with 4 (7.8%) in the no AF group, 7 (19.4%) in the PAF
group, and 7 (36.8%) in the PeAF group. There were a
total of 28 hospitalizations, with 0.38 hospitalizations
per patient year. During regression analysis, PAF was
not associated with an increased risk of HF hospitali-
zation (HR: 2.18; 95% CI: 0.64 to 7.47; p ¼ 0.21), but
PeAF was a signiﬁcant predictor of HF hospitalization
(HR: 7.37; 95% CI: 2.12 to 25.64; p ¼ 0.002). LVAD
implant creatinine level (HR: 1.69; 95% CI: 1.26 to 2.26;
p< 0.001) and diabetes mellitus (HR: 3.36; 95% CI: 1.25
to 9.06; p ¼ 0.02) also were predictors of HF
hospitalization.
ATRIAL FIBRILLATION AND FUNCTIONAL STATUS.
Thirty-ﬁve patients (33.0%) had a CPET performed
at a median of 134 days (IQR: 109 to 231 days)eath in Patients Stratiﬁed by AF Status
No AF
n ¼ 9/51 (17.6%)
Paroxysmal AF
n ¼ 5/36 (13.9%)
Persistent AF
n ¼ 7/19 (36.8%)
3 (33.3) 0 (0.0) 1 (14.3)
3 (33.3) 1 (20.0) 3 (42.9)
2 (22.2) 1 (20.0) 0 (0.0)
e 0 (0.0) 1 (20.0) 1 (14.3)
0 (0.0) 1 (20.0, CVA) 1 (14.3, pump thrombus)
1 (11.1) 1 (20.0) 1 (14.3)
VA ¼ cerebrovascular accident.post-LVAD implantation. The median peak VO2 for
this group was 13.6 (range: 4.0 to 21.4) ml/kg/min.
Nineteen patients (54.3%) without AF, 9 patients
(25.7%) with PAF, and 7 patients (20.0%) with PeAF
underwent CPET. Only patients with PeAF were in
AF at the time of the study. Median peak Vo2 in the
PeAF group (11.2 [IQR: 8.7 to 14] ml/kg/min) was
lower than in the no AF and PAF groups (13.8 [IQR:
12.7 to 16] ml/kg/min and 14.2 [IQR: 10.8 to 15]
ml/kg/min, respectively) (Figure 2). However, there
were no statistically signiﬁcant differences in peak
Vo2 between the groups (p ¼ 0.13 for PeAF versus no
AF; p ¼ 0.46 for PeAF versus PAF; and p ¼ 0.42 for
PAF versus no AF) or in peak Vo2 between those in AF
and those not in AF during the CPET (median peak
Vo2: 11.2 versus 14.0 ml/kg/min; p ¼ 0.17). There were
also no signiﬁcant differences between the median
respiratory exchange ratios of the 3 groups (1.00 [IQR:
0.93 to 1.09] for no AF; 0.92 [IQR: 0.9 to 1.0] for PAF;
and 0.94 [IQR: 0.9 to 1.03] for PeAF).
ATRIAL FIBRILLATION, BLEEDING, AND THROMBO-
EMBOLISM. Thirty-one patients (29.2%) experienced
55 bleeding events during follow-up, with 0.75
events per patient year. Sixteen patients (15.1%) had
21 thromboembolic events during follow-up, with
0.28 events per patient year. Characteristics of
bleeding and thromboembolic events stratiﬁed by
AF status are shown in Table 4. Thirteen patients
(25.5%) without AF, 13 (36.1%) with PAF, and 5
(26.3%) with PeAF experienced bleeding events. TheNo AF Paroxysmal AF Persistent AF
5
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FIGURE 2 Box Plot of Peak VO2 During
Cardiopulmonary Exercise Testing Stratiﬁed by AF Status
The middle line in the box represents the median, and the lower
and upper lines represent the 25th and 75th percentiles,
respectively. Bars represent the 10th and 90th percentiles, and
dots are outliers. AF ¼ atrial ﬁbrillation; VO2 ¼ oxygen
consumption.
TABLE 4 Characteristics of Bleeding and Thromboembolic Events Stratiﬁed by
AF Status (n ¼ 106)
Characteristic No AF (n ¼ 51)
Paroxysmal
AF (n ¼ 36)
Persistent
AF (n ¼ 19)
Bleeding
Patients 13 (25.5) 13 (36.1) 5 (26.3)
Events 20 23 12
Patients with >1 event 5 6 2
Mean INR  at time of event 2.14  0.97,
1.2–5.1
2.53  1.20,
1.5–6.7
2.28  0.96,
1.1–4.8
Gastrointestinal bleeding occurrences
(% of events)
13 (65.0) 16 (69.6) 10 (83.3)
Intracranial hemorrhage occurrences
(% of events)
2 (10.0) 2 (8.7) 1 (8.3)
Other incidents (% of events) 4 (20.0) 5 (21.7) 1 (8.3)
Episodes requiring procedural intervention 9 (45.0) 9 (39.1) 3 (25.0)
Thromboembolism
Patients 9 (17.7%) 6 (16.7) 1 (5.3)
Events 11 9 1
Patients with >1 event 2 2 0
INR at time of event 1.54  0.34,
1.1–2.2
2.72  0.99*,
1.6–4.4
2.5
Mean 4 week INR prior to event 1.57  0.31,
1.3–2.1
2.36  0.69*,
1.6–3.5
2.1
Stroke (% of events) 6 (54.6) 7 (77.8) 1 (100.0)
LVAD thrombus 4 (36.4) 1 (11.1) 0 (0.0)
Other arterial thromboembolism 1 (9.1) 1 (11.1) 0 (0.0)
Values are %, n, mean  SD, or range. p > 0.05 for all group comparisons for bleeding events. *p < 0.05 for
paroxysmal AF versus no AF.
INR ¼ international normalized ratio; other abbreviations as in Table 1.
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1887majority of episodes (70.9%) were gastrointestinal,
with many requiring endoscopic intervention. ICH
was the cause in 9.1% of the episodes, and 18.1%
were from other causes, primarily signiﬁcant
epistaxis. There were no signiﬁcant differences in
the type of bleeding event or in the INR at the time
of the bleeding event between patients with no AF,
PAF, and PeAF (Table 4). There were also no signif-
icant differences in survival free from major
bleeding among the 3 groups (Figure 3A) (log-rank:
p ¼ 0.70). In regression analysis, the development
of new AF post-LVAD (HR: 3.63; 95% CI: 1.26 to
10.45; p ¼ 0.02) and implant creatinine level (HR:
1.36; 95% CI: 1.08 to 1.61; p < 0.01) were signiﬁcant
predictors of bleeding. There was also a strong trend
toward increased bleeding in patients with post-
LVAD thromboembolism (HR: 2.23; 95% CI: 1.0 to
5.0; p ¼ 0.05).
In terms of thromboembolism, 9 patients (17.7%)
without AF, 6 (16.7%) with PAF, and 1 (5.3%) with PeAF
had thromboembolic events. The majority of episodes
were due to CVA (61.9%) followed by LVAD thrombosis
(28.6%) (Table 4). One episode (4.8%) was due to a
popliteal arterial embolus, and another (4.8%)was due
to LV apical thrombus. There were no signiﬁcant dif-
ferences in the type of thromboembolism or in survival
free from thromboembolism among the 3 groups
(Figure 3B) (log-rank: p¼0.48). Because therewas only
1 event in the PeAF group, INRs were compared be-
tween patients with PAF or PeAF and those without
AF. Patients with any AF had a higher INR both at the
time of the thromboembolic event (2.70  0.94 vs.
1.54  0.34; p ¼ 0.003) and for the 4 weeks leading up
to the event (2.33  0.65 vs. 1.57  0.31; p ¼ 0.006)
(Figure 4). In regression analysis, there was a trend
toward increased risk for thromboembolism in pa-
tients with post-LVAD bleeding, but this did not quite
reach statistical signiﬁcance (HR: 2.52; 95% CI: 0.94 to
6.74; p ¼ 0.06).
DISCUSSION
Our study has 3 primary ﬁndings. First, PAF was not
associated with an increased risk of death, HF hos-
pitalization, bleeding, or thromboembolism. Second,
PeAF was an independent predictor of death or HF
hospitalization. Third, despite a higher level of anti-
coagulation therapy, patients with any AF had nearly
the same number of thromboembolic events as those
without AF (Central Illustration). To our knowledge,
this is the ﬁrst study to show an increased risk of
mortality or HF hospitalization with AF in this patient
population and the ﬁrst to support a higher target INR
in patients with AF.It has long been recognized that AF and chronic
HF are interrelated. AF can worsen symptoms of
HF by reducing ventricular ﬁlling through loss of
atrial systole, decreasing diastolic ﬁlling time, and
impairing systolic function. In turn, decompensated
HF also can aggravate AF, leading to rapid ventric-
ular response. With this interplay, it is not surprising
that AF has been associated with increased mortality
and HF hospitalization in patients with chronic HF
(3,7). However, this ﬁnding has not been consistent
(8,9). One possible reason for this discrepancy is that
the type of AF was not differentiated in many
studies. In the SOLVD (Studies of Left Ventricular
Dysfunction) trial, AF was deﬁned as AF present on
the pre-randomization electrocardiogram (3). This
deﬁnition likely selected for PeAF patients, and the
study found that AF was associated with an
increased risk of the composite endpoint of death or
HF hospitalization.
Results from our study are similar to those from
SOLVD. Although PAF was not associated with an
increased risk of reaching the composite endpoint of
death or HF hospitalization, PeAF was an indepen-
dent predictor of the composite endpoint (HR: 3.54;
p < 0.01). This ﬁnding was driven in large part by an
0.00
0.25
0.50
0.75
1.00
Su
rv
iv
al
 F
re
e 
fr
om
 B
le
ed
in
g
0 100 200 300 400
Support Time
Number at risk
No AF
Paroxysmal AF
Persistent AF
51
36
19
34
22
8
20
12
5
9
7
3
6
5
2
Log-rank: p = 0.70
0.00
0.25
0.50
0.75
1.00
Su
rv
iv
al
 F
re
e 
fr
om
Th
ro
m
bo
em
bo
lis
m
0 100 200 300 400
Support Time
Number at risk
No AF
Paroxysmal AF
Persistent AF
51
36
19
37
25
10
25
18
7
14
13
5
8
10
4
Log-rank: p = 0.48
No AF Persistent AFParoxysmal AF
A
B
FIGURE 3 Kaplan-Meier Event-Free Survival Curves for
Bleeding and Thromboembolism
Kaplan-Meier event-free survival curves are shown for
(A) bleeding and (B) thromboembolism stratiﬁed by atrial
ﬁbrillation status. Abbreviation as in Figure 1.
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in Figure 1.
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1888increased risk of HF hospitalization in patients with
PeAF (HR: 7.37; p < 0.01), but there was also a strong
trend toward increased mortality in patients with
PeAF (HR: 2.65; p ¼ 0.06). These results suggest that
the AF burden is of great importance in this patient
population. An analysis using a quantitation of AF
burden would have been ideal, but this was not
possible because these data were unavailable for
many patients.
Only 1 other study has examined the effect of AF on
mortality in CF-LVAD patients. In a study of 389 pa-
tients with a CF-LVAD, Stulak et al. (4) reported that
preoperative AF was not associated with increased
mortality. However, AF was not subclassiﬁed into
PAF and PeAF in the study, which potentially ex-
plains the discrepant result. No other studies have
examined the association of AF and HF hospitaliza-
tion in CF-LVAD patients.
The cause of the trend toward increased mortality
in patients with PeAF is unclear. Patients with PeAFwere more likely to be older, have chronic kidney
disease, and have had a diagnosis of HF for more than
1 year. It is possible that PeAF is simply a marker for
sicker patients with worse outcomes after LVAD im-
plantation, as sepsis was the primary cause of death
in the PeAF group (Table 3). The increased risk of
HF hospitalization in patients with PeAF in our
study suggests that the RV may remain sensitive to
the hemodynamic effects of AF despite CF-LVAD
support. Hemodynamic compromise from AF with
improvement after catheter ablation in a patient with
a CF-LVAD has been reported (10). The trend toward
lower peak VO2 in PeAF patients also suggests a
possible hemodynamic effect of AF. However, the
number of patients undergoing CPET in our study was
very small, and the effect of AF on functional status
warrants further study.
Although patients with AF had a higher target INR
level in our study, there were no differences in
bleeding events. This result underlies the observation
that acquired von Willebrand disease plays a major
role in bleeding in patients with CF-LVADs, and a
relatively small difference in target INR may be less
contributory (11). It is also important to note that the
rate of major bleeding was lower in our cohort than in
other studies (12). In our study, the rate of thrombo-
embolic events was 0.28 events per patient year,
which is slightly higher than that in other studies
(12,13). An important ﬁnding in our study is that pa-
tients with AF experienced thromboembolic events at
PAROXYSMAL AF PERSISTENT AF
AF in patients
with the
HM II LVAD
ADVERSE CLINICAL
OUTCOMES
Potential effects:
  • Decreased RV output
  • Higher target INR levels
  • Increased risk of TE
No increased risk of:
    Death
    HF hospitalization
    Bleeding
TE events occurred 
at signif icantly higher 
INR levels compared 
to those without AF
Increased risk of:
     Death
     HF hospitalization
No increased risk of:
     Bleeding
Enriquez, A.D., et al., J Am Coll Cardiol. 2014; 64(18):1883–90.
CENTRAL ILLUSTRATION Impact of AF on LVAD Patients
AF may lead to adverse clinical outcomes in HM II patients through a variety of adverse effects (Left). Study results (Right): paroxysmal AF was
not associated with worse outcomes, but persistent AF was associated with an increased risk of death or HF hospitalization. Patients with any
AF had TE events at higher INRs. AF ¼ atrial ﬁbrillation; INR ¼ international normalized ratio; HF ¼ heart failure; HM II ¼ HeartMate II; LVAD ¼
left ventricular assist device; RV ¼ right ventricular; TE ¼ thromboembolism.
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1889signiﬁcantly higher INR levels than those without AF.
Despite this higher level of anticoagulation, the
number of events between the 2 groups was nearly
identical, suggesting an increased risk of thrombo-
embolism with AF. This is consistent with the only
other study examining thromboembolism and AF in
patients with CF-LVADs, as Stulak et al. (4) reported
an increased risk of thromboembolism with preoper-
ative AF (HR: 1.89; p < 0.01). It is also interesting to
note that in our study, thromboembolism was a pre-
dictor of bleeding and vice versa. This relationship
has been shown before in LVAD patients and un-
derscores the need for ﬁnding the optimal level of
anticoagulation (14).
Our study may have implications for the manage-
ment of patients with CF-LVADs. If PeAF is associated
with increased mortality and worsening HF, patients
may beneﬁt from a more aggressive rhythm control
strategy to reduce the burden of AF. Consideration
should be given to performing surgical Cryo-Maze at
the time of LVAD implantation, more liberal use of
antiarrhythmic drugs, and even catheter ablation inselect patients. Although our study was not designed
to determine the optimal level of anticoagulation, our
results support targeting a higher INR in patients
with AF.
STUDY LIMITATIONS. Our study has several impor-
tant limitations. First, this study is retrospective and
non-randomized and therefore subject to selection
bias and confounding with the data limited by docu-
mentation in the chart. There were a relatively
small number of patients and outcomes, and the
ﬁndings should be considered only exploratory and
hypothesis-generating. Second, the major positive
ﬁnding in our study was found with subgroup anal-
ysis. Thus, the ﬁndings are less signiﬁcant, although
the p values for the composite endpoint were robust.
Third, the generalizability of our results is somewhat
limited. More than 85% of the patients in our study
had the HMII implanted as a bridge to trans-
plantation, and all of the patients had a HMII
implanted with INR goals based on our institutional
policy. Therefore, our bleeding and thromboembo-
lism results may not be applicable with different
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: AF
develops in up to 50% of patients with CF-LVADs.
Although paroxysmal AF is not associated with
appreciable worsening of clinical outcomes, persis-
tent AF may be associated with more frequent
hospitalization for decompensated heart failure and
higher rates of mortality. Patients with AF may also
have thromboembolic events at signiﬁcantly higher
INR levels.
TRANSLATIONAL OUTLOOK: Prospective studies
are needed to evaluate the relative safety and efﬁcacy
of more intensive anticoagulation and/or more
aggressive rhythm control strategies in patients with
CF-LVADs who develop persistent AF.
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1890target INR levels or in patients with the other
commercially available CF-LVAD (HeartWare HVAD,
Framingham, Massachusetts).
CONCLUSIONS
AF is common in patients with CF-LVADs. Although
PAF is not associated with worse clinical outcomes,
PeAF may be associated with increased mortality and
hospitalization for HF. Although PAF and PeAF are
not associated with a signiﬁcantly increased risk of
bleeding or thromboembolic events, patients with
any AF may have thromboembolic events at higher
INR levels. Prospective studies with monitoring of AF
burden are needed to conﬁrm our results.
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